Bausch & Lomb Maintains Stock Rating Following Pipeline Data Review
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowH.C. Wainwright reiterated its Buy rating and $21.00 price target on Bausch & Lomb (BLCO) after reviewing new pipeline data. The Phase 2 trial of the company's dual-action eye drop did not meet its primary endpoint at Day 29, but secondary analysis data at Day 15 was strong enough to advance the candidate into a Phase 3 program in 2027. H.C. Wainwright cited this data, along with the drug's projected peak sales potential, in maintaining its positive rating.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
